Frequency of Non-Type I/II CALR Mutations in Patients Undergoing Molecular Diagnostics for Myeloproliferative Neoplasms
Diseases · 28.05.2026 · 14 (6) · 190
DOI: 10.3390/diseases14060190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diseases, online erschienen am 28.05.2026. Verfasst von Tatiana Makarik und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Medical Research Center for Hematology, 125167 Moscow, Russia. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Somatic CALR gene insertions/deletions in exon 9, causing frameshift, are a diagnostic sign of myeloproliferative neoplasms (MPNs). Besides the most common somatic mutations of type I (52 bp deletion) and type II (5 bp insertion), there are rare ones whose significance is not always clear. This study evaluates the frequency of rare mutations and demonstrates a germline rather than somatic nature for some of them.
Methods
A retrospective analysis of 8417 blood samples subjected to molecular diagnosis of myeloproliferative neoplasm (MPN) was performed. Cases suspected as germline variants were sequenced, and paired samples (when available) of buccal epithelium were analyzed.
Results
We have identified 632 CALR gene mutation-positive cases. Most of the cases were typical insertions/deletions (5 bp/52 bp). Non-type I/II frameshift or nonframeshift mutations were observed in 68 cases (11%). The buccal swab samples obtained from 4 patients confirmed the germline nature of these variants. It is worth noting that the MPN diagnosis for three of these patients was made considering the presence of the JAK2 V617F mutation (two cases) or BCR::ABL1 translocation (one case). In one case, the diagnosis of MPN was reclassified to CML.
Conclusions
Non-type I/II CALR mutations, according to our data, could be found in 0.8% of MPN-suspected cases, and may not be associated with the diagnosis. The detection of a non-standard CALR mutation with an allelic frequency close to 50% should raise suspicion of the possibility of a germline CALR variant, and such cases should be investigated further.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Medical Research Center for Hematology, 125167 Moscow, Russia.
- Moscow Multidisciplinary Clinical Center "Kommunarka", 108814 Moscow, Russia.
ORCID-Profile: Bella Biderman, Andrey Sudarikov
Zitieren
APA
Makarik, T., Nikulina, E., Treglasova, S., Stepanova, E., Chernova, N., Biderman, B., Kokhno, A., & Sudarikov, A. (2026). Frequency of Non-Type I/II CALR Mutations in Patients Undergoing Molecular Diagnostics for Myeloproliferative Neoplasms. Diseases, 14(6), 190. https://doi.org/10.3390/diseases14060190
Vancouver
Makarik T, Nikulina E, Treglasova S, Stepanova E, Chernova N, Biderman B, et al. Frequency of Non-Type I/II CALR Mutations in Patients Undergoing Molecular Diagnostics for Myeloproliferative Neoplasms. Diseases. 2026;14(6):190. doi:10.3390/diseases14060190
BibTeX
@article{Makarik2026,
author = {Makarik, Tatiana and Nikulina, Elena and Treglasova, Svetlana and Stepanova, Elena and Chernova, Natalia and Biderman, Bella and Kokhno, Alina and Sudarikov, Andrey},
title = {Frequency of Non-Type I/II CALR Mutations in Patients Undergoing Molecular Diagnostics for Myeloproliferative Neoplasms},
journal = {Diseases},
year = {2026},
volume = {14},
number = {6},
pages = {190},
doi = {10.3390/diseases14060190}
}
EUVIMED